Minireviews
Copyright ©The Author(s) 2021.
World J Clin Cases. Jun 26, 2021; 9(18): 4491-4499
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4491
Table 1 Prevalence and sustained virologic response after hepatitis C virus treatment in patients with hepatitis C virus monoinfection compared to patients with hepatitis C virus/human immunodeficiency virus coinfection

HCV monoinfection
HCV/HIV coinfection
Prevalence184 million person worldwide2.3 million person worldwide
SVR after interferon treatment36%-76% (genotype 1, 2, 3, 4, treatment naïve)18.4%-50% (genotype 1, 2, 3, 4, treatment naïve)
SVR after DAA treatment96%-100% (pangenotype, treatment naïve)95%-98% (pangenotype, treatment naïve)
Table 2 Drug-drug interaction between antiretroviral drugs and direct-acting antiviral agents
Antiretroviral drugs
SOF/LED
SOF/VEL
SOF/VEL/VOX
EBR/GZR
GLE/PIB
NRTIs
Tenoforvir disoproxil fumarate--
NNRTIs
Efavarenz-XXXX
Etravirenz-XXXX
Nevirapine-XXXX
Protease inhibitors
Atazanavir/ritonavir--XXX
Atazanavir/cobicistat --XXX
Darunavir/ritonavir--XXX
Darunavir/cobicistat---XX
Lopinavir/ritonavir--XXX